Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer
Join David D. Chism, MD, MS and Peter E. Clark from Vanderbilt-Ingram Cancer Center as they present their expertise on a range of cases pertaining to bladder cancer.
Bladder cancer is the most common urological cancer. In 2015, an estimated 74,000 new patients were diagnosed with bladder cancer in the United States, and 16,000 died from it. Greater accuracy of staging and grading of bladder cancer in recent years has been shown to be a critical component to improving patient outcomes as it allows for implementation of optimal treatment strategies. Treatment of bladder cancer has expanded with the use of bladder-preserving strategies to improve quality of life and the continued modification of neoadjuvant, adjuvant and maintenance regimens. Though treatment strategies continue to advance, many therapeutic strategies remain available only on a clinical trial. Clinicians need to remain knowledgeable about evolving therapeutic options and be able to discuss the risks and benefits of clinical trials with patients.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Recognize the critical role of grading and staging bladder cancer and identify additional factors that affect prognosis, disease management and therapeutic options when developing treatment plans for patients with bladder cancer.
- Select evolving immunotherapeutic approaches as appropriate to optimize current adjuvant and neoadjuvant treatment strategies.
- Counsel patients on available clinical trials and encourage participation when appropriate.
David D. Chism, MD, MS
Vanderbilt-Ingram Cancer Center
Peter E. Clark
Vanderbilt-Ingram Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below has no relevant financial relationships to disclose:
David D. Chism, MD, MS
The faculty listed below have disclosed the following relevant financial relationships:
Peter E. Clark, MD
Galil Medical: Scientific Advisor
Genentech, Inc.: Scientific Advisor
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Mary A. Dwyer, MS
The NCCN clinical information team listed below, who have reviewed content, has the following relevant financial relationships to disclose:
Courtney Smith, PhD
Johnson & Johnson, Opko Health Inc, ICON plc: Equity Interest/Stock Options
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.80 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-084-H01-P
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.80 ANCC contact hours
- 0.75 Participation